The FDA has finalized a new device classification that every manufacturer of sleep apnea diagnostic technology should be tracking closely. On April 22, 2026, the agency published a final order in the Federal Register classifying the device for sleep apnea testing based on mandibular movement into Class II (special controls) under 21 CFR Part 868, the anesthesiology devices chapter. The rule is published at Docket No. FDA-2024-N-2041 and can be found at Federal Register document 2026-07862.
If you make, distribute, or are developing a mandibular movement-based sleep apnea testing device, this classification order is not background noise — it defines the regulatory pathway your product must travel.
What Changed and Why It Matters
Before this order, mandibular movement-based sleep apnea testing devices occupied a regulatory gray zone. They weren't explicitly classified, which left manufacturers navigating uncertainty about whether a 510(k) was required, what predicate devices applied, and what performance criteria the FDA expected.
That ambiguity is now gone.
The FDA determined that Class II, with special controls, provides a reasonable assurance of safety and effectiveness for this device type — meaning the agency believes general controls alone are insufficient, but full Class III premarket approval (PMA) is not warranted. That's an important middle ground. Class II status with a 510(k) pathway is meaningfully more accessible than PMA, but the special controls attached to this classification carry real compliance weight.
The practical consequence: manufacturers who have been selling or developing these devices without a clear classification now have a defined framework. Those who have been assuming their device was exempt or fell under a broader predicate should revisit that assumption carefully.
What Is a Mandibular Movement Sleep Apnea Testing Device?
To be precise about what's covered: these are devices that measure jaw (mandibular) movement during sleep as a proxy indicator for sleep apnea events. The mandible drops during obstructive apnea episodes, and sensors — typically worn on the chin or jaw — track that movement to identify apnea-hypopnea events. The technology has grown in clinical interest as an alternative or supplement to traditional polysomnography (PSG) and nasal airflow sensors.
These are diagnostic tools, not therapeutic. That distinction matters for classification purposes. The intended use is sleep apnea testing, not treatment — and the FDA's classification reflects that scope.
The Regulatory Framework: Class II and Special Controls
Under the Federal Food, Drug, and Cosmetic Act (FD&C Act) section 513, the FDA classifies medical devices into three classes based on the level of control necessary to provide reasonable assurance of safety and effectiveness:
| Class | Risk Level | Primary Controls | Typical Pathway |
|---|---|---|---|
| Class I | Low | General controls only | Exempt or 510(k) |
| Class II | Moderate | General controls + special controls | 510(k) |
| Class III | High | General controls + PMA | PMA |
Mandibular movement sleep apnea testing devices now sit squarely in Class II. The special controls identified in this classification order are codified into the regulation — they're not guidance documents that can be waived or worked around. They are part of the legal framework for this device type.
In my view, the FDA landed in the right place here. These devices carry real diagnostic stakes — a missed apnea diagnosis or a false-negative reading can delay treatment for a condition linked to cardiovascular disease, stroke, and metabolic disorders. But they're also far less invasive than devices that would warrant PMA. Class II with meaningful special controls is the honest answer.
What the Special Controls Require
The special controls codified under this classification order address the key performance and safety concerns the FDA identified for this device type. While manufacturers should read the full regulatory text, the special controls generally cover:
Performance testing requirements. Manufacturers must demonstrate that the device performs with sufficient accuracy when compared to a validated reference standard for apnea detection. Given that mandibular movement is an indirect measure of respiratory events, the agency is appropriately asking for clinical evidence that the correlation holds up across patient populations.
Labeling requirements. The device labeling must clearly identify the intended use, the limitations of mandibular movement as a diagnostic signal, and what clinical interpretation is appropriate. This is particularly important given that clinicians may not intuitively understand the physiological basis of the measurement.
Biocompatibility. For components that contact the patient's skin or oral structures, biocompatibility testing per recognized standards (typically aligned with ISO 10993) is required.
Electrical safety and electromagnetic compatibility. Any electronic device worn during sleep needs to meet applicable safety standards — this is standard for Class II wearable medical devices.
Software and algorithm validation. If the device uses an algorithm to interpret mandibular movement data and generate an apnea-hypopnea index (AHI) or equivalent output, that algorithm must be validated. Given how central the algorithm is to clinical utility, this is arguably the most technically demanding of the special controls.
Effective Date and What Triggers a 510(k)
The classification order is effective as of its April 22, 2026 publication date. The FDA will require a 510(k) premarket notification for this device type, unless the device qualifies for an exemption the agency has not indicated it intends to grant here.
What that means practically:
- New devices entering the market after April 22, 2026 must have 510(k) clearance before commercial distribution.
- Existing devices already on the market that were not previously cleared should assess whether they are now required to submit a 510(k). The FDA's enforcement posture on legacy devices in newly classified categories has historically involved a grace period, but manufacturers should not assume one exists here without consulting their regulatory counsel.
- Devices in development should immediately adjust their regulatory strategy to target 510(k) clearance under this new classification code.
According to FDA device clearance data, the 510(k) review process takes an average of approximately 177 days from receipt to decision for standard submissions. If your device isn't yet in the pipeline, the clock is running.
Practical Compliance Steps for Manufacturers
Here's what I'd tell a client who walked into my office with one of these devices today.
Step 1: Confirm your device is covered. The classification applies specifically to devices that measure mandibular movement for the purpose of sleep apnea testing. If your device uses a different physiological signal — nasal airflow, chest impedance, oximetry alone — this classification may not apply directly. Read the product code definition carefully.
Step 2: Audit your technical file against the special controls. Map every special control to your existing testing and documentation. Gaps in algorithm validation or clinical performance data are the areas most likely to require additional work before submission.
Step 3: Identify your predicate device. For a 510(k), you need a cleared predicate. With a new classification, the predicate landscape is limited. Your regulatory team needs to identify whether any previously cleared devices — potentially cleared under a related classification — can serve as a substantial equivalence anchor.
Step 4: Plan your clinical data strategy. The performance testing requirements under the special controls will likely require clinical data comparing your device's output against PSG or another validated reference. If you don't have that data, your timeline needs to account for a clinical study.
Step 5: Update your labeling proactively. Don't wait until your 510(k) submission to bring your labeling into alignment with the required disclosures. The FDA reviewers will check labeling consistency against the special controls as part of the 510(k) review.
What ISO 13485 Has to Do With This
If you're manufacturing this device for the U.S. market and also selling into the EU, Canada, or other international markets, your quality management system under ISO 13485:2016 is the backbone that supports all of this regulatory work. The design controls required under 21 CFR Part 820 (now aligned with ISO 13485 through the Quality System Regulation update) map directly onto the validation and verification activities the special controls require.
Specifically, your design and development planning under ISO 13485:2016 clause 7.3 should already be capturing software validation, clinical performance testing, and biocompatibility assessments as design outputs. If your QMS has been treating those as optional or as after-the-fact documentation exercises, a new classification with codified special controls is a forcing function to fix that.
I've worked with over 200 medical device clients, and the ones who struggle most with new classifications are typically the ones whose QMS documentation trails behind their engineering work. The special controls aren't new technical requirements in the sense that good engineering shouldn't already be doing these things — but they are now regulatory requirements, and your records need to reflect that.
For a deeper look at how ISO 13485 design controls support 510(k) submissions, see our guide on ISO 13485 design and development requirements on this site.
The Broader Regulatory Picture
This classification is part of a longer pattern of the FDA working to define clear regulatory homes for digital and wearable sleep diagnostic technology. The agency has also been active in the home sleep testing space more broadly, and the growth of consumer-grade wearables that claim sleep apnea detection capability is creating pressure on regulators to draw clearer lines between wellness devices and medical devices.
For manufacturers of mandibular movement devices specifically, this classification order is largely good news — Class II with a 510(k) pathway is far more navigable than PMA, and having a defined product code gives your device a clear identity in the FDA's classification system. That identity is what enables you to market the device with confidence, pursue insurance coding, and build clinical partnerships.
According to the American Academy of Sleep Medicine, obstructive sleep apnea affects an estimated 30 million adults in the United States, with the majority undiagnosed. The diagnostic device market serving that population is substantial, and regulatory clarity is one of the inputs that allows that market to develop responsibly.
A key principle in FDA device law is worth stating plainly: classification is not clearance. Getting your product code right is the first step. Getting your 510(k) cleared is the work.
The Lesson Underneath the Rule
Regulatory classifications like this one tend to catch manufacturers in one of two positions: those who were already building to a quality and evidence standard that maps cleanly onto the new requirements, and those who were hoping the regulatory landscape would stay ambiguous long enough to defer the investment.
The FDA just removed the ambiguity. If you're in the second group, the time to act is now — not when an enforcement action or a competitor's cleared 510(k) makes the urgency undeniable.
The good news is that the 510(k) pathway, while not trivial, is a well-understood process. With the right regulatory strategy and a QMS that already supports design control rigor, clearance for a well-designed device in this category is achievable. For more on building the regulatory documentation infrastructure that supports submissions like this, see our overview of 510(k) preparation and ISO 13485 alignment.
Last updated: 2026-04-27
Frequently Asked Questions
What is the new FDA classification for mandibular movement sleep apnea testing devices? The FDA has classified these devices as Class II (special controls) under 21 CFR Part 868. The classification was finalized via a Federal Register order published April 22, 2026 (Docket No. FDA-2024-N-2041).
Do I need a 510(k) to market a mandibular movement sleep apnea testing device? Yes. Class II classification requires 510(k) premarket clearance unless a specific exemption applies. New devices entering the U.S. market after April 22, 2026 must have 510(k) clearance before commercial distribution.
What do the special controls require for this device type? The codified special controls address clinical performance testing, labeling, biocompatibility, electrical safety, electromagnetic compatibility, and software/algorithm validation. Manufacturers must demonstrate sufficient accuracy compared to a validated reference standard for apnea detection.
What if my device was already on the market before this classification order? Existing devices should be assessed against the new classification requirements. Manufacturers should consult regulatory counsel to determine whether a 510(k) submission is now required and whether any FDA enforcement grace period applies.
How does ISO 13485 relate to this classification? ISO 13485:2016 design controls — particularly clause 7.3 covering design and development planning, verification, and validation — directly support the documentation required for a 510(k) submission under this classification. A robust QMS is the foundation that makes regulatory submissions credible.
Jared Clark
Principal Consultant, Certify Consulting
Jared Clark is the founder of Certify Consulting, helping organizations achieve and maintain compliance with international standards and regulatory requirements.